Geode Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.08M Buy
1,483,787
+40,822
+3% +$267K ﹤0.01% 2606
2026
Q1
$9.97M Buy
1,442,965
+51,175
+4% +$395K ﹤0.01% 2381
2025
Q4
$12.3M Sell
1,391,790
-295
-0% -$1.62K ﹤0.01% 2304
2025
Q3
$6.95M Sell
1,392,085
-299,553
-18% -$1.39M ﹤0.01% 2617
2025
Q2
$7.99M Buy
1,691,638
+77,997
+5% +$341K ﹤0.01% 2488
2025
Q1
$7.41M Buy
1,613,641
+163,331
+11% +$761K ﹤0.01% 2463
2024
Q4
$6.95M Buy
1,450,310
+24,483
+2% +$118K ﹤0.01% 2571
2024
Q3
$6.69M Buy
1,425,827
+94,870
+7% +$509K ﹤0.01% 2599
2024
Q2
$7.52M Buy
1,330,957
+85,575
+7% +$442K ﹤0.01% 2499
2024
Q1
$5.12M Sell
1,245,382
-121
-0% -$484 ﹤0.01% 2692
2023
Q4
$5.26M Buy
1,245,503
+66,248
+6% +$267K ﹤0.01% 2681
2023
Q3
$5.1M Buy
1,179,255
+44,331
+4% +$246K ﹤0.01% 2631
2023
Q2
$7.48M Buy
1,134,924
+52,393
+5% +$336K ﹤0.01% 2469
2023
Q1
$7.35M Buy
1,082,531
+29,941
+3% +$211K ﹤0.01% 2446
2022
Q4
$7.78M Buy
1,052,590
+26,077
+3% +$254K ﹤0.01% 2424
2022
Q3
$10.1M Buy
1,026,513
+9,345
+0.9% +$98.7K ﹤0.01% 2247
2022
Q2
$11.1M Buy
1,017,168
+4,727
+0.5% +$49K ﹤0.01% 2177
2022
Q1
$11.4M Sell
1,012,441
-14,817
-1% -$195K ﹤0.01% 2262
2021
Q4
$16.1M Buy
1,027,258
+16,554
+2% +$288K ﹤0.01% 2099
2021
Q3
$17.3M Buy
1,010,704
+6,342
+0.6% +$111K ﹤0.01% 2054
2021
Q2
$21.6M Buy
1,004,362
+38,948
+4% +$697K ﹤0.01% 1910
2021
Q1
$14.5M Buy
965,414
+113,991
+13% +$1.85M ﹤0.01% 2089
2020
Q4
$11.2M Buy
851,423
+33,581
+4% +$404K ﹤0.01% 2095
2020
Q3
$7.9M Buy
817,842
+11,924
+1% +$127K ﹤0.01% 2111
2020
Q2
$9.22M Buy
805,918
+43,693
+6% +$495K ﹤0.01% 1962
2020
Q1
$7.9M Buy
762,225
+1,663
+0.2% +$20.6K ﹤0.01% 1885
2019
Q4
$12.5M Buy
760,562
+3,323
+0.4% +$50.2K ﹤0.01% 1856
2019
Q3
$10.1M Buy
757,239
+29,354
+4% +$409K ﹤0.01% 1933
2019
Q2
$10.3M Buy
727,885
+88,791
+14% +$1.41M ﹤0.01% 1937
2019
Q1
$11.8M Buy
639,094
+42,468
+7% +$968K ﹤0.01% 1790
2018
Q4
$15.6M Buy
596,626
+6,666
+1% +$157K ﹤0.01% 1456
2018
Q3
$13.5M Buy
589,960
+25,040
+4% +$511K ﹤0.01% 1703
2018
Q2
$10.8M Buy
564,920
+63,774
+13% +$1.07M ﹤0.01% 1813
2018
Q1
$8.44M Buy
501,146
+102,100
+26% +$1.71M ﹤0.01% 1887
2017
Q4
$6.07M Sell
399,046
-26,998
-6% -$401K ﹤0.01% 2099
2017
Q3
$7.63M Sell
426,044
-6,010
-1% -$101K ﹤0.01% 1934
2017
Q2
$7.04M Buy
432,054
+19,530
+5% +$281K ﹤0.01% 1898
2017
Q1
$5.78M Buy
412,524
+23,941
+6% +$341K ﹤0.01% 2004
2016
Q4
$6.2M Buy
388,583
+16,274
+4% +$262K ﹤0.01% 1915
2016
Q3
$6.2M Buy
372,309
+4,652
+1% +$62.6K ﹤0.01% 1828
2016
Q2
$4.11M Sell
367,657
-12,014
-3% -$116K ﹤0.01% 2046
2016
Q1
$3.17K Buy
379,671
+31,939
+9% +$262K ﹤0.01% 2155
2015
Q4
$3.24M Buy
347,732
+66,261
+24% +$661K ﹤0.01% 2167
2015
Q3
$3.17M Sell
281,471
-14,074
-5% -$172K ﹤0.01% 2138
2015
Q2
$3.75M Buy
295,545
+71,473
+32% +$771K ﹤0.01% 2099
2015
Q1
$2.08M Buy
224,072
+2,967
+1% +$33.5K ﹤0.01% 2413
2014
Q4
$3.17M Buy
221,105
+27,365
+14% +$324K ﹤0.01% 2116
2014
Q3
$2.01M Buy
193,740
+2,248
+1% +$29.5K ﹤0.01% 2358
2014
Q2
$3.1M Buy
191,492
+1,563
+0.8% +$20.8K ﹤0.01% 2107
2014
Q1
$3.09M Buy
189,929
+5,113
+3% +$72.7K ﹤0.01% 2075
2013
Q4
$2.29M Buy
184,816
+4,751
+3% +$47.7K ﹤0.01% 2217
2013
Q3
$1.98M Buy
180,065
+7,362
+4% +$78.7K ﹤0.01% 2177
2013
Q2
$1.4M Buy
+172,703
New +$1.16M ﹤0.01% 2265

Other funds holding VNDA

Geode Capital Management's VNDA Position: Q2 2026 in Review

Geode Capital Management increased its Vanda Pharmaceuticals (VNDA) stake by 2.8% in Q2 2026, buying an estimated $267K and bringing the position to 1,483,787 shares worth $9.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2606.

Geode Capital Management first reported a position in VNDA in Q2 2013 and has held it in 53 quarters since. The position peaked at $21.6M in Q2 2021. 171 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Geode Capital Management held 1,483,787 shares of Vanda Pharmaceuticals worth $9.08M as of Q2 2026.
  • Geode Capital Management bought 40,822 Vanda Pharmaceuticals shares in Q2 2026, an estimated $267K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2606 holding.
  • Geode Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Geode Capital Management's Vanda Pharmaceuticals position peaked at $21.6M in Q2 2021.
  • 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.